Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Intellia has reported results from a phase 2 trial of its gene ... who said the data "underscore[s] the tremendous potential of [the] in vivo CRISPR gene editing therapy" and "sets NTLA-2002 ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

According to InvestingPro data, the company maintains ... Successful clinical trials in autoimmune diseases could significantly enhance CRISPR Therapeutics' market position. The company's CTX112 ...

With the promising data we’ve presented thus far ... placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema (HAE).

CRISPR and Vertex have obtained approval for clinical trial applications for several ... Novartis yesterday unveiled data showing its crizanlizumab reduced occurrence of the painful and ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and ...

On multiple occasions, Kennedy has commented on the potential of CRISPR ... haven’t been borne out by data from drugs that are moving through clinical trials and beginning to reach patients ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...